Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS. Changes in the ...

Belite Bio completes enrollment in phase 2/3 DRAGON II clinical trial evaluating tinlarebant for the treatment of Stargardt ...

Please provide your email address to receive an email when new articles are posted on . Science Corporation reported positive preliminary results of a clinical trial examining its Prima retinal ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, is pleased to announce the ...

Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious adverse events reported across the Phase 1 and Phase 2 ...

Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on ...

The new DNA test means there is no reason why another English Shepherd Dog ever needs to be born with progressive retinal atrophy, which causes total blindness. Progressive retinal atrophy (PRA) is a ...